Key result
Survival machine learning models incorporating hyperuricemia achieve ~0.99 AUC for predicting PTS after unprovoked DVT.
Why the study?
Post-thrombotic syndrome after unprovoked DVT lacks readily available, calibrated risk estimates at defined follow-up horizons.
Can survival machine-learning models incorporating hyperuricemia accurately predict post-thrombotic syndrome after unprovoked DVT?
Can survival machine-learning models incorporating hyperuricemia accurately predict post-thrombotic syndrome after unprovoked DVT?
Survival machine-learning models incorporating hyperuricemia provide highly accurate and calibrated risk estimates for post-thrombotic syndrome following unprovoked DVT.
Answers are grounded in this paper and cite their sources.
May aid PTS risk stratification after unprovoked DVT; leaves open external validation before clinical use.
Background/Objectives: Post-thrombotic syndrome (PTS) following unprovoked deep vein thrombosis (DVT) lacks readily available, calibrated risk estimates at defined follow-up horizons. Building on signals that thrombus burden, care processes, and a form of metabolic–inflammatory tone influence outcomes, we prospectively evaluated survival machine-learning models, explicitly including hyperuricemia while excluding what we consider major inflammatory confounders. Methods: Adults with first-episode unprovoked lower-extremity DVT were enrolled at two centers (July 2024–September 2025). PTS (Villalta) was assessed at 3, 6, 9, and 12 months. The cohort was split 70/30 into training and test sets. Eight learners (RSF, GBM, LASSO + Cox, CoxBoost, survivalsvm, XGBoost-Cox, superpc, and plsRcox) were tuned using 10-fold cross-validation in training and once evaluated in the independent test set. Performance metrics included all time-dependent AUCs, fixed-time ROC AUCs with bootstrap 95% CIs, C-index, various forms of calibration, decision-curve analysis, and simple Kaplan–Meier risk group separation. Results: 193 patients were analyzed (PTS in 64%). High 9-month AUCs were seen in training: GBM (0.992) and RSF (0.982) being the strongest; by 12 months, both remained near constant. Test set performance followed a similar pattern, with RSF again favored (AUC 0.948) and XGBoost/GBM close behind. Calibration was satisfactory, net benefit from decision curves positive, and to a large extent, risk groups were separated as expected. Conclusions: Survival machine-learning models, at least in this dual-center prospective cohort, produced a clinically useful risk of PTS. Hyperuricemia, or any metabolically based signal, is a valuable addition to the “anatomy and care” of DVT. External validation is still required.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question. Survival machine-learning models, incorporating hyperuricemia, achieved a 9-month AUC of 0.992 for predicting post-thrombotic syndrome after unprovoked DVT.
Synapse has enriched 10 related papers. Consider them for comparative context: